KeyNote 189 is the first clinical trial demonstrating the promising therapeutic effects of chemoimmunotherapy compared with chemotherapy alone in nonsquamous NSCLC, in which pembrolizumab in combination with platinum‐based chemotherapy significantly improved the OS and PFS of NSCLC patients without EGFR or ALK mutations.300. This evidence concerns the gene ALK and non-small cell lung carcinoma.